Facet Life Sciences
Consultancy providing regulatory strategy, submission preparation, development planning, and commercialization support for small and mid-size life sciences companies. Core services include regulatory affairs and FDA interactions, medical and submission writing, biostatistics/biometrics, CMC strategy, asset valuation/HEOR, program gap analysis, and access to execution partners across drugs, biologics, devices, radiopharmaceuticals, and combination products.
Industries
Nr. of Employees
small (1-50)
Facet Life Sciences
Philadelphia, Pennsylvania, United States
Products
Facet Life Sciences Regulatory Consulting Services
Facet Life Sciences offers expert regulatory consulting services tailored for emerging biotech companies, focusing on FDA regulatory strategy, clinical study design, and evidence planning to optimize drug development timelines and costs.
FDA Meeting Consulting Services
Expert consulting services by Facet Life Sciences to help emerging life sciences companies prepare for and navigate FDA meetings, ensuring strategic milestones and better FDA outcomes.
Product Development Champion
The Regulatory Affairs Manager (called a Product Development Champion [PDC] at Facet) helps emerging companies advance their drug, biologic, device, and combination products through regulated development stages, including FDA submissions and clinical plans.
Diagnostic & Theranostic Radiopharmaceutical Services
Consulting services specializing in the development and regulatory approval of diagnostic and therapeutic radiopharmaceuticals, including strategic program guidance, FDA meeting support, IND and NDA document authoring, and eCTD submission.
Asset Valuation Services
Facet Life Sciences offers expert asset valuation services to help small life sciences companies maximize and grow the full potential of their product at every stage of development, from early R&D to market maturity.
NDA Gap Analysis
A consulting service by Facet Life Sciences to identify and fix gaps in New Drug Application submissions before filing, improving chances of FDA approval.
Facet Life Sciences Regulatory Consulting Services
Facet Life Sciences offers expert regulatory consulting services tailored for emerging biotech companies, focusing on FDA regulatory strategy, clinical study design, and evidence planning to optimize drug development timelines and costs.
FDA Meeting Consulting Services
Expert consulting services by Facet Life Sciences to help emerging life sciences companies prepare for and navigate FDA meetings, ensuring strategic milestones and better FDA outcomes.
Product Development Champion
The Regulatory Affairs Manager (called a Product Development Champion [PDC] at Facet) helps emerging companies advance their drug, biologic, device, and combination products through regulated development stages, including FDA submissions and clinical plans.
Diagnostic & Theranostic Radiopharmaceutical Services
Consulting services specializing in the development and regulatory approval of diagnostic and therapeutic radiopharmaceuticals, including strategic program guidance, FDA meeting support, IND and NDA document authoring, and eCTD submission.
Asset Valuation Services
Facet Life Sciences offers expert asset valuation services to help small life sciences companies maximize and grow the full potential of their product at every stage of development, from early R&D to market maturity.
NDA Gap Analysis
A consulting service by Facet Life Sciences to identify and fix gaps in New Drug Application submissions before filing, improving chances of FDA approval.
Services
Strategic and tactical regulatory support across product development stages, including regulatory strategy, FDA engagement, and pathway planning.
Authoring and quality control of regulatory submission documents (CMC, nonclinical, clinical), FDA responses, and meeting materials prepared from a reviewer-focused perspective.
Biostatistics and biometric services including trial simulations, endpoint selection, SAP development, SAS programming, and regulatory statistical representation.
Market assessment, HEOR planning, pricing and reimbursement strategy, launch planning, and investor-aligned asset valuation.
Objective evaluation of development programs to identify gaps, risks, and mitigation plans with timelines and cost estimates.
Act as a contracted U.S. regulatory agent to facilitate communications with FDA for sponsors without a U.S. presence.
Strategic and tactical regulatory support across product development stages, including regulatory strategy, FDA engagement, and pathway planning.
Authoring and quality control of regulatory submission documents (CMC, nonclinical, clinical), FDA responses, and meeting materials prepared from a reviewer-focused perspective.
Biostatistics and biometric services including trial simulations, endpoint selection, SAP development, SAS programming, and regulatory statistical representation.
Market assessment, HEOR planning, pricing and reimbursement strategy, launch planning, and investor-aligned asset valuation.
Objective evaluation of development programs to identify gaps, risks, and mitigation plans with timelines and cost estimates.
Act as a contracted U.S. regulatory agent to facilitate communications with FDA for sponsors without a U.S. presence.
Expertise Areas
- Regulatory strategy and FDA interactions
- Regulatory submission preparation and medical writing
- Clinical trial design and biostatistics
- CMC strategy and manufacturing readiness
Key Technologies
- eCTD submission preparation
- Clinical trial simulation and modeling
- Adaptive and innovative trial design methodologies
- SAS programming and biometric analysis
News & Updates
Published articles and resources covering FDA meeting types, breakthrough therapy designation, radiopharmaceuticals, orphan drug development, and regulatory partnership announcements.
Certification badges displayed on company website for multiple periods (e.g., May 2023–May 2024 and April 2024–April 2025).
Awards and recognitions displayed on company website for regulatory services.
Published articles and resources covering FDA meeting types, breakthrough therapy designation, radiopharmaceuticals, orphan drug development, and regulatory partnership announcements.
Certification badges displayed on company website for multiple periods (e.g., May 2023–May 2024 and April 2024–April 2025).
Awards and recognitions displayed on company website for regulatory services.